These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33383993)

  • 1. The Application of Philip Morris' Litigation Prevention Program in South Korea.
    Kim JH; Kim J; Lee S
    Asia Pac J Public Health; 2021; 33(2-3):188-195. PubMed ID: 33383993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of the third wave of tobacco litigation in the United States, 1994-2005.
    Douglas CE; Davis RM; Beasley JK
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv9-16. PubMed ID: 17130629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARTIST (Asian regional tobacco industry scientist team): Philip Morris' attempt to exert a scientific and regulatory agenda on Asia.
    Tong EK; Glantz SA
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii118-24. PubMed ID: 15564214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry.
    Tong EK; England L; Glantz SA
    Pediatrics; 2005 Mar; 115(3):e356-66. PubMed ID: 15741361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tobacco Industry's Abuse of Scientific Evidence and Activities to Recruit Scientists During Tobacco Litigation.
    Lee S
    J Prev Med Public Health; 2016 Jan; 49(1):23-34. PubMed ID: 26841882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating demand for foreign brands in a 'home run' market: tobacco company tactics in South Korea following market liberalisation.
    Lee S; Lee K; Holden C
    Tob Control; 2014 May; 23(3):e8. PubMed ID: 23152099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turning free speech into corporate speech: Philip Morris' efforts to influence U.S. and European journalists regarding the U.S. EPA report on secondhand smoke.
    Muggli ME; Hurt RD; Becker LB
    Prev Med; 2004 Sep; 39(3):568-80. PubMed ID: 15313097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public versus internal conceptions of addiction: An analysis of internal Philip Morris documents.
    Elias J; Hendlin YH; Ling PM
    PLoS Med; 2018 May; 15(5):e1002562. PubMed ID: 29715300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobacco industry lawyers as "disease vectors".
    Guardino SD; Daynard RA
    Tob Control; 2007 Aug; 16(4):224-8. PubMed ID: 17652236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tobacco industry and underage youth smoking: tobacco industry documents from the Minnesota litigation.
    Perry CL
    Arch Pediatr Adolesc Med; 1999 Sep; 153(9):935-41. PubMed ID: 10482208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobacco industry strategies to undermine the 8th World Conference on Tobacco or Health.
    Muggli ME; Hurt RD
    Tob Control; 2003 Jun; 12(2):195-202. PubMed ID: 12773731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Litigation in Argentina: challenging the tobacco industry.
    Flores ML; Barnoya J; Mejia R; Alderete E; Pérez-Stable EJ
    Tob Control; 2006 Apr; 15(2):90-6. PubMed ID: 16565455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tobacco advertising and promotion: themes employed in litigation by tobacco industry witnesses.
    Goldberg ME; Davis RM; O'Keefe AM
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv54-67. PubMed ID: 17130625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying lessons from tobacco litigation to obesity lawsuits.
    Alderman J; Daynard RA
    Am J Prev Med; 2006 Jan; 30(1):82-8. PubMed ID: 16414429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hiding in the Shadows: Philip Morris and the Use of Third Parties to Oppose Ingredient Disclosure Regulations.
    Velicer C; Glantz SA
    PLoS One; 2015; 10(12):e0142032. PubMed ID: 26717245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation.
    Velicer C; Lempert LK; Glantz S
    Tob Control; 2015 Sep; 24(5):469-80. PubMed ID: 24920577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Big tobacco "pull out all stops" for a landmark example: The Burswood Casino case.
    Laura B; Julia S; Mike D
    Australas Med J; 2011; 4(12):645-54. PubMed ID: 22905040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Living Tomorrow Project: how Philip Morris has used a Belgian tourist attraction to promote ventilation approaches to the control of second hand smoke.
    Pilkington P; Gilmore AB
    Tob Control; 2004 Dec; 13(4):375-8. PubMed ID: 15564621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding Philip Morris's pursuit of US government regulation of tobacco.
    McDaniel PA; Malone RE
    Tob Control; 2005 Jun; 14(3):193-200. PubMed ID: 15923470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.